ADC Therapeutics SA filings document the regulatory record of a Swiss commercial-stage biotechnology company with common shares listed on the New York Stock Exchange. Its Form 8-K reports cover operating results, preliminary financial information, Regulation FD presentations, clinical data updates for ZYNLONTA studies, and material agreements including amendments to royalty financing arrangements.
Proxy materials describe annual general meeting matters under Swiss law, including approval of annual and consolidated financial statements, compensation report votes, discharge of directors and executive committee members, board and compensation committee elections, auditor matters and share capital governance. The filings also identify the company’s registered common shares, par value and exchange listing.
ADC Therapeutics SA entered into securities purchase agreements for a $60.0 million private placement of equity to institutional investors. The Company will sell 11,250,000 common shares at $4.00 per share and pre-funded warrants to purchase 3,846,153 common shares at $3.90 per warrant. Closing is expected on October 27, 2025, subject to customary conditions.
The Company agreed to file a registration statement within 30 business days to register the resale of the common shares and the common shares issuable upon exercise of the pre-funded warrants. The pre-funded warrants are exercisable until the tenth anniversary at an exercise price of CHF 0.08 per share, include a 9.99% beneficial ownership cap (which holders may increase to 19.99% after 61 days’ notice), and permit cashless exercise under specified conditions.
ADC Therapeutics SA is registering 1,000,000 additional common shares, each with a par value of CHF 0.08, for issuance under the ADC Therapeutics SA Inducement Plan. This Form S-8 uses General Instruction E, meaning it adds to a previously registered pool of shares rather than creating a new plan from scratch.
The company incorporates by reference its latest Annual Report on Form 10-K, its two most recent Quarterly Reports on Form 10-Q, and certain Current Reports on Form 8-K, so those filings provide the detailed financial and business information for plan participants. The filing also includes legal opinions and consents, and is signed by the chief executive officer and other senior officers and directors, authorizing the registration of these additional inducement equity awards.
ADC Therapeutics SA furnished a current report to let investors know it has made an updated corporate presentation available. The presentation, dated September 30, 2025, is attached as Exhibit 99.1. The company notes that this material is being provided under Regulation FD and is not considered filed for liability purposes under the Exchange Act.
Redmile Group and affiliated entities report significant holdings in ADC Therapeutics SA. The Schedule 13G/A discloses that Redmile Group, LLC and Jeremy C. Green collectively have shared voting and dispositive power over 15,666,731 common shares, representing 14.0% of the outstanding common stock on the basis described in the filing. One affiliated fund, RedCo II Master Fund, L.P., is reported with shared power over 13,145,712 shares (11.7%). The filing states these shares are held by private investment vehicles managed by Redmile and that both Redmile Group and Mr. Green disclaim direct beneficial ownership except to the extent of any pecuniary interest. The percentage calculations use the issuer's reported outstanding shares plus a recent private placement.
ADC Therapeutics SA filed a Form S-8 on August 12, 2025 to register 4,850,000 additional common shares (par value CHF 0.08) for issuance under the ADC Therapeutics SA 2019 Equity Incentive Plan. The filing incorporates by reference prior Form S-8 registrations filed on March 15, 2023 and June 30, 2022 and references periodic reports filed in 2025.
Exhibits listed include amended and restated articles, a Swiss counsel opinion, the consent of PricewaterhouseCoopers SA, the amended plan and a filing fee table.
ADC Therapeutics reported consolidated revenue of $18.8 million for the quarter and $41.9 million for the six months, driven by U.S. product sales of ZYNLONTA and increased license/royalty income. The company recorded a net loss of $56.6 million for the quarter and $95.2 million for the six months, reflecting higher R&D spending and a $13.1 million charge for restructuring and impairments tied to a plan to close the UK facility and reduce global headcount by approximately 30%.
Liquidity was strengthened by a June private placement that generated gross $100.0 million (net $93.1 million), leaving cash and cash equivalents at $264.6 million. Material longer-term obligations include a deferred royalty obligation (fair value ~$312.0 million, carrying balance rolled to $340.4 million in the rollforward) and senior secured term loans with a carrying value of $114.5 million and an effective interest rate of 16.15%. Shareholders' deficit was $(199.2) million at June 30, 2025.
ADC Therapeutics SA reported that it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The company filed a Current Report on Form 8-K to attach that press release as Exhibit 99.1, and the filing also includes a Cover Page Interactive Data File as Exhibit 104.
The filing states that the information in Item 2.02 and Exhibit 99.1 is incorporated by reference but shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. The report is signed on behalf of the company by Jose Carmona, Chief Financial Officer. The 8-K itself does not include the detailed financial tables or results within the body of the filing.